Adherence to treatment recommendations from a referral center for myelodysplastic syndromes (MDS)

被引：0
|
作者：
Kasprzak, A. [1 ]
Kondakci, M. [1 ]
Nachtkamp, K. [1 ]
Kobbe, G. [1 ]
Schroeder, T. [1 ]
Kuendgen, A. [1 ]
Kaivers, J. [1 ]
Rautenberg, C. [1 ]
Haas, R. [1 ]
Gattermann, N. [1 ]
Germing, U. [1 ]
机构：
[1] Univ Hosp Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V202
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [41] Cytogenetic changes in myelodysplastic syndromes (MDS)
    Haus, O
    Kotlarek-Haus, S
    Czarnecka, M
    Potoczek, S
    Kyrcz-Krzemien, S
    Duszenko, E
    Makowska, I
    CYTOGENETICS AND CELL GENETICS, 1999, 85 (1-2): : 71 - 71
  • [42] Recent advances in myelodysplastic syndromes (MDS)
    Ascari, E
    HAEMATOLOGICA, 1998, 83 (03) : 287 - 288
  • [43] Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
    Malcovati, Luca
    Hellstrom-Lindberg, Eva
    Bowen, David
    Ades, Lionel
    Cermak, Jaroslav
    del Canizo, Consuelo
    Della Porta, Matteo G.
    Fenaux, Pierre
    Gattermann, Norbert
    Germing, Ulrich
    Jansen, Joop H.
    Mittelman, Moshe
    Mufti, Ghulam
    Platzbecker, Uwe
    Sanz, Guillermo F.
    Selleslag, Dominik
    Skov-Holm, Mette
    Stauder, Reinhard
    Symeonidis, Argiris
    van de Loosdrecht, Arjan A.
    de Witte, Theo
    Cazzola, Mario
    BLOOD, 2013, 122 (17) : 2943 - 2964
  • [44] The pathogenesis of myelodysplastic syndromes (MDS): insights from a network view
    Ren, Xianwen
    Zhou, Xiaobo
    Wu, Lingyun
    Zhang, Xiang-Sun
    Wong, Stephen
    Chang, Chung-Che
    CANCER RESEARCH, 2009, 69
  • [45] RESPONSE TO RECOMBINANT-HUMAN-ERYTHROPOIETIN TREATMENT IN MYELODYSPLASTIC SYNDROMES (MDS)
    HAST, R
    CELSING, F
    EKMAN, M
    STENKE, L
    JOURNAL OF INTERNAL MEDICINE, 1991, 229 (04) : 381 - 382
  • [46] Oral idarubicin and GM-CSF for the treatment of myelodysplastic syndromes (MDS).
    Somasundram, U
    Hazel, D
    Newland, AC
    Hughes, A
    Boots, M
    Watts, E
    McMillan, AK
    Janmohammed, R
    Johnson, S
    Samson, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 77 - 77
  • [47] Influence of different treatment strategies on the prognosis of patients with myelodysplastic syndromes (MDS)
    Nachtkamp, K.
    Kuendgen, A.
    Strupp, C.
    Gattermann, N.
    Giagounidis, A.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2007, 31 : S30 - S30
  • [48] Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS)
    Candoni, A.
    Raza, A.
    Galili, N.
    Simeone, E.
    Buttignol, S.
    Silvestri, F.
    Fanin, R.
    LEUKEMIA RESEARCH, 2007, 31 : S119 - S119
  • [49] Iron chelation treatment in patients with myelodysplastic syndromes (MDS): the experience of the Hellenic MDS Study Group
    Kouraklis, A.
    Symeonidis, A.
    Galanopoulos, A.
    Kaiafa, G.
    Tavernarakis, I.
    Tsirakis, G.
    Michali, E.
    Tsaftaridis, P.
    Loukidis, K.
    Aggelidis, A.
    Zoumbos, N.
    LEUKEMIA RESEARCH, 2009, 33 : S119 - S120
  • [50] Need of transfusions, treatment and survival of patients with Myelodysplastic Syndromes (MDS): Update of the outpatient MDS registry
    Steinmetz, H. T.
    Boettger, I
    Lathan, B.
    Sauer, A.
    Severin, K.
    Germing, U.
    Schmitz, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 234 - 234
12345